2nd Annual Genomics Meeting
The IMS Genomics Meeting was developed in response to the IMS-FDA joint workshop to further consider essential needs in myeloma. The initial invitation-only meeting in 2023 provided an opportunity for myeloma experts from around the world to develop a consensus to define ‘high-risk multiple myeloma’. The publication with the results and recommendations from this meeting has been submitted for review. Building upon this success, the Second IMS Genomics Meeting will be a public meeting led by global myeloma KOL.
In addition to which, this day and a half-long meeting will include sessions on:
- Risk Stratification validation
- Genomically targeted therapies
- New technologies
- Genomic Biomarkers for stratification of clinical studies
- New clinical trials for patients with HR disease